Negative modulation of invariant natural killer T cell responses to glycolipid antigens by p38 MAP kinase

International Immunopharmacology

Volumn 10, Issue 9, 2010, Pages 1068-1076

  Stuart, Jason K ^a   Bisch, Steven P ^a   Leon Ponte, Matilde ^a   Hayatsu, Jin ^a   Mazzuca, Delfina M ^a   Maleki Vareki, Saman ^a   Haeryfar, S M Mansour ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

galactosylceramide; MAPK; NKT cell; P38; Signaling

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 6 (4 FLUOROPHENYL) 2,3 DIHYDRO 5 (4 PYRIDYL)IMIDAZO[2,1 B]THIAZOLE; ALPHA GALACTOSYLCERAMIDE; ANTIGEN; CD1D ANTIGEN; GAMMA INTERFERON; GLYCOLIPID; INTERLEUKIN 2; INTERLEUKIN 4; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; MONOCLONAL ANTIBODY CD3; STRESS ACTIVATED PROTEIN KINASE; T LYMPHOCYTE RECEPTOR;

ANIMAL CELL; ANTIGEN PRESENTATION; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; ENZYME INHIBITION; IMMUNE RESPONSE; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE; MOUSE; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SPLEEN CELL; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTHRACENES; ANTIBODIES; ANTIGEN PRESENTATION; ANTIGENS; ANTIGENS, CD1D; ANTIGENS, CD3; CYTOKINES; DOWN-REGULATION; ENZYME INHIBITORS; FLAVONOIDS; GALACTOSYLCERAMIDES; IMIDAZOLES; INTERFERON-GAMMA; INTERLEUKIN-2; INTERLEUKIN-4; MICE; MICE, INBRED C57BL; NATURAL KILLER T-CELLS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN KINASE INHIBITORS; PYRIDINES; RECEPTORS, ANTIGEN, T-CELL; SPLEEN;

EID: 77955923293     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2010.06.007     Document Type: Article

References (52)

1. Lanier L.L., Chang C., Phillips J.H. Human NKR-P1A. A disulfide-linked homodimer of the C-type lectin superfamily expressed by a subset of NK and T lymphocytes. J Immunol 1994, 153:2417-2428.
2. Bendelac A., Savage P.B., Teyton L. The biology of NKT cells. Annu Rev Immunol 2007, 25:297-336.
3. Fowlkes B.J., Kruisbeek A.M., Ton-That H., et al. A novel population of T-cell receptor alpha beta-bearing thymocytes which predominantly expresses a single V beta gene family. Nature 1987, 329:251-254.
4. Lantz O., Bendelac A. An invariant T cell receptor alpha chain is used by a unique subset of major histocompatibility complex class I-specific CD4+ and CD4-8- T cells in mice and humans. J Exp Med 1994, 180:1097-1106.
5. Kronenberg M. Toward an understanding of NKT cell biology: progress and paradoxes. Annu Rev Immunol 2005, 23:877-900.
6. Zeng Z., Castano A.R., Segelke B.W., Stura E.A., Peterson P.A., Wilson I.A. Crystal structure of mouse CD1: an MHC-like fold with a large hydrophobic binding groove. Science 1997, 277:339-345.
7. Matsuda J.L., Gapin L., Baron J.L., et al. Mouse V alpha 14i natural killer T cells are resistant to cytokine polarization in vivo. Proc Natl Acad Sci USA 2003, 100:8395-8400.
8. Stetson D.B., Mohrs M., Reinhardt R.L., et al. Constitutive cytokine mRNAs mark natural killer (NK) and NK T cells poised for rapid effector function. J Exp Med 2003, 198:1069-1076.
9. Parekh V.V., Singh A.K., Wilson M.T., et al. Quantitative and qualitative differences in the in vivo response of NKT cells to distinct alpha- and beta-anomeric glycolipids. J Immunol 2004, 173:3693-3706.
10. Berkers C.R., Ovaa H. Immunotherapeutic potential for ceramide-based activators of iNKT cells. Trends Pharmacol Sci 2005, 26:252-257.
11. Kawano T., Cui J., Koezuka Y., et al. CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science 1997, 278:1626-1629.
12. Hong C., Park S.H. Application of natural killer T cells in antitumor immunotherapy. Crit Rev Immunol 2007, 27:511-525.
13. Terabe M., Berzofsky J.A. The role of NKT cells in tumor immunity. Adv Cancer Res 2008, 101:277-348.
14. Haeryfar S.M. Invariant natural killer T cells in immune surveillance and tumor immunotherapy: perspectives and potentials. Arch Iran Med 2008, 11:186-195.
15. Veldt B.J., van d V., von Blomberg B.M., et al. Randomized placebo controlled phase I/II trial of alpha-galactosylceramide for the treatment of chronic hepatitis C. J Hepatol 2007, 47:356-365.
16. Woltman A.M., Ter Borg M.J., Binda R.S., et al. Alpha-galactosylceramide in chronic hepatitis B infection: results from a randomized placebo-controlled Phase I/II trial. Antivir Ther 2009, 14:809-818.
17. Dong C., Davis R.J., Flavell R.A. MAP kinases in the immune response. Annu Rev Immunol 2002, 20:55-72.
18. Zhang Y., Dong C. Regulatory mechanisms of mitogen-activated kinase signaling. Cell Mol Life Sci 2007, 64:2771-2789.
19. Bogoyevitch M.A., Boehm I., Oakley A., Ketterman A.J., Barr R.K. Targeting the JNK MAPK cascade for inhibition: basic science and therapeutic potential. Biochim Biophys Acta 2004, 1697:89-101.
20. Peifer C., Wagner G., Laufer S. New approaches to the treatment of inflammatory disorders small molecule inhibitors of p38 MAP kinase. Curr Top Med Chem 2006, 6:113-149.
21. Cui J., Shin T., Kawano T., et al. Requirement for Valpha14 NKT cells in IL-12-mediated rejection of tumors. Science 1997, 278:1623-1626.
22. Lee J.C., Laydon J.T., McDonnell P.C., et al. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 1994, 372:739-746.
23. Zhang N., Ahsan M.H., Zhu L., Sambucetti L.C., Purchio A.F., West D.B. Regulation of IkappaBalpha expression involves both NF-kappaB and the MAP kinase signaling pathways. J Inflam (Lond) 2005, 2:10.
24. Seeger F.H., Sedding D., Langheinrich A.C., Haendeler J., Zeiher A.M., Dimmeler S. Inhibition of the p38 MAP kinase in vivo improves number and functional activity of vasculogenic cells and reduces atherosclerotic disease progression. Basic Res Cardiol 2010, 105:389-397.
25. Ward K.W., Prokscht J.W., Azzaranot L.M., et al. Preclinical pharmacokinetics of SB-203580, a potent inhibitor of p38 mitogen-activated protein kinase. Xenobiotica 2001, 31:783-797.
26. Eberl G., Lowin-Kropf B., MacDonald H.R. Cutting edge: NKT cell development is selectively impaired in Fyn-deficient mice. J Immunol 1999, 163:4091-4094.
27. Gadue P., Morton N., Stein P.L. The Src family tyrosine kinase Fyn regulates natural killer T cell development. J Exp Med 1999, 190:1189-1196.
28. Felices M., Berg L.J. The Tec kinases Itk and Rlk regulate NKT cell maturation, cytokine production, and survival. J Immunol 2008, 180:3007-3018.
29. Ashwell J.D. The many paths to p38 mitogen-activated protein kinase activation in the immune system. Nat Rev Immunol 2006, 6:532-540.
30. Dudley D.T., Pang L., Decker S.J., Bridges A.J., Saltiel A.R. A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc Natl Acad Sci USA 1995, 92:7686-7689.
31. Haeryfar S.M., Hoskin D.W. Selective pharmacological inhibitors reveal differences between Thy-1- and T cell receptor-mediated signal transduction in mouse T lymphocytes. Int Immunopharmacol 2001, 1:689-698.
32. Bennett B.L., Sasaki D.T., Murray B.W., et al. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc Natl Acad Sci USA 2001, 98:13681-13686.
33. Zhang J., Salojin K.V., Gao J.X., Cameron M.J., Bergerot I., Delovitch T.L. p38 mitogen-activated protein kinase mediates signal integration of TCR/CD28 costimulation in primary murine T cells. J Immunol 1999, 162:3819-3829.
34. Renukaradhya G.J., Webb T.J., Khan M.A., et al. Virus-induced inhibition of CD1d1-mediated antigen presentation: reciprocal regulation by p38 and ERK. J Immunol 2005, 175:4301-4308.
35. Smith K.G., Austyn J.M., Hariri G., Beverley P.C., Morris P.J. T cell activation by anti-T3 antibodies: comparison of IgG1 and IgG2b switch variants and direct evidence for accessory function of macrophage Fc receptors. Eur J Immunol 1986, 16:478-486.
36. Zhang J., Shen B., Lin A. Novel strategies for inhibition of the p38 MAPK pathway. Trends Pharmacol Sci 2007, 28:286-295.
37. Hsu S.C., Gavrilin M.A., Tsai M.H., Han J., Lai M.Z. p38 mitogen-activated protein kinase is involved in Fas ligand expression. J Biol Chem 1999, 274:25769-25776.
38. Hu M.C., Wang Y.P., Mikhail A., Qiu W.R., Tan T.H. Murine p38-delta mitogen-activated protein kinase, a developmentally regulated protein kinase that is activated by stress and proinflammatory cytokines. J Biol Chem 1999, 274:7095-7102.
39. Ivaska J., Reunanen H., Westermarck J., Koivisto L., Kahari V.M., Heino J. Integrin alpha2beta1 mediates isoform-specific activation of p38 and upregulation of collagen gene transcription by a mechanism involving the alpha2 cytoplasmic tail. J Cell Biol 1999, 147:401-416.
40. Cohen P. Targeting protein kinases for the development of anti-inflammatory drugs. Curr Opin Cell Biol 2009, 21:317-324.
41. Van K.L. alpha-Galactosylceramide therapy for autoimmune diseases: prospects and obstacles. Nat Rev Immunol 2005, 5:31-42.
42. Bessoles S., Fouret F., Dudal S., Besra G.S., Sanchez F., Lafont V. IL-2 triggers specific signaling pathways in human NKT cells leading to the production of pro- and anti-inflammatory cytokines. J Leukoc Biol 2008, 84:224-233.
43. Joshi S.K., Lang G.A., Larabee J.L., et al. Bacillus anthracis lethal toxin disrupts TCR signaling in CD1d-restricted NKT cells leading to functional anergy. PLoS Pathog 2009, 5:e1000588.
44. Borg N.A., Wun K.S., Kjer-Nielsen L., et al. CD1d-lipid-antigen recognition by the semi-invariant NKT T-cell receptor. Nature 2007, 448:44-49.
45. Godfrey D.I., MacDonald H.R., Kronenberg M., Smyth M.J., Van K.L. NKT cells: what's in a name?. Nat Rev Immunol 2004, 4:231-237.
46. Crowe N.Y., Coquet J.M., Berzins S.P., et al. Differential antitumor immunity mediated by NKT cell subsets in vivo. J Exp Med 2005, 202:1279-1288.
47. Brossay L., Chioda M., Burdin N., et al. CD1d-mediated recognition of an alpha-galactosylceramide by natural killer T cells is highly conserved through mammalian evolution. J Exp Med 1998, 188:1521-1528.
48. Schmieg J., Yang G., Franck R.W., Tsuji M. Superior protection against malaria and melanoma metastases by a C-glycoside analogue of the natural killer T cell ligand alpha-Galactosylceramide. J Exp Med 2003, 198:1631-1641.
49. Miyamoto K., Miyake S., Yamamura T. A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells. Nature 2001, 413:531-534.
50. Yu K.O., Im J.S., Molano A., et al. Modulation of CD1d-restricted NKT cell responses by using N-acyl variants of alpha-galactosylceramides. Proc Natl Acad Sci USA 2005, 102:3383-3388.
51. Denkberg G., Stronge V.S., Zahavi E., et al. Phage display-derived recombinant antibodies with TCR-like specificity against alpha-galactosylceramide and its analogues in complex with human CD1d molecules. Eur J Immunol 2008, 38:829-840.
52. McCarthy C., Shepherd D., Fleire S., et al. The length of lipids bound to human CD1d molecules modulates the affinity of NKT cell TCR and the threshold of NKT cell activation. J Exp Med 2007, 204:1131-1144.